Top Markets
Coin of the day
Scopus BioPharma Inc. Scopus BioPharma Inc.

Scopus BioPharma Inc.

SCPS
Rangering i aksjer #41540
Scopus BioPharma Inc. is a biopharmaceutical company in the clinical... Scopus BioPharma Inc. is a biopharmaceutical company in the clinical development phase, dedicated to pioneering innovative treatments for serious diseases. Its core development programs are concentrated on immuno-oncology gene therapies designed to combat various forms of cancer. The company's offerings include the Duet Platform, which incorporates CpG signal transducer and activator of transcription 3 (STAT3) inhibitors. Another significant product is MRI-1867, a cleverly engineered, orally administered, dual-action hybrid small molecule. MRI-1867 functions as an inverse agonist of the endocannabinoid system's cannabinoid receptor 1 (CB1) and additionally acts as an inhibitor of inducible nitric oxide synthase (iNOS). To advance its key development efforts and other programs, Scopus BioPharma has established strategic collaborations with prominent organizations such as the City of Hope, the National Institutes of Health Program, and The Hebrew University of Jerusalem. Established in 2017, the company was originally named Project18 Inc. before officially rebranding to Scopus BioPharma Inc. in December of that year. Its corporate headquarters are located in New York, New York.
Aksjekurs
$0.0004
Sist synkronisert: 2026-08-11
Markedsverdi
$16.83K
Endring (1 dag)
0.00%
Endring (1 år)
33.33%
Land
US
Handel Scopus BioPharma Inc. (SCPS)

Kategori

EPS for Scopus BioPharma Inc. (SCPS)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Scopus BioPharma Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Scopus BioPharma Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter